Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy

Shakti D. Shukla; Steven L. Taylor; Peter G. Gibson; Daniel Barker; John W. Upham; Ian A. Yang; Paul N. Reynolds; Sandra Hodge; Alan L. James; Geraint B. Rogers; Jodie L. Simpson

doi:10.1136/thoraxjnl-2020-216331

Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy

Shakti D. Shukla, Steven L. Taylor, Peter G. Gibson, Daniel Barker, John W. Upham, Ian A. Yang, Paul N. Reynolds, Sandra Hodge, Alan L. James, Geraint B. Rogers, Jodie L. Simpson

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

Original language	English
Pages (from-to)	733-736
Number of pages	4
Journal	Thorax
Volume	76
Issue number	7
Early online date	7 Jan 2021
DOIs	https://doi.org/10.1136/thoraxjnl-2020-216331
Publication status	Published - 1 Jul 2021

Keywords

asthma
asthma pharmacology
cytokine biology
respiratory infection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/thoraxjnl-2020-216331Licence: In Copyright

Cite this

@article{ca7634c4690840ada72f9664fd4a1d50,

title = "Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy",

abstract = "Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy. ",

keywords = "asthma, asthma pharmacology, cytokine biology, respiratory infection",

author = "Shukla, {Shakti D.} and Taylor, {Steven L.} and Gibson, {Peter G.} and Daniel Barker and Upham, {John W.} and Yang, {Ian A.} and Reynolds, {Paul N.} and Sandra Hodge and James, {Alan L.} and Rogers, {Geraint B.} and Simpson, {Jodie L.}",

year = "2021",

month = jul,

day = "1",

doi = "10.1136/thoraxjnl-2020-216331",

language = "English",

volume = "76",

pages = "733--736",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "7",

}

TY - JOUR

T1 - Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma

T2 - An AMAZES substudy

AU - Shukla, Shakti D.

AU - Taylor, Steven L.

AU - Gibson, Peter G.

AU - Barker, Daniel

AU - Upham, John W.

AU - Yang, Ian A.

AU - Reynolds, Paul N.

AU - Hodge, Sandra

AU - James, Alan L.

AU - Rogers, Geraint B.

AU - Simpson, Jodie L.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

AB - Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

KW - asthma

KW - asthma pharmacology

KW - cytokine biology

KW - respiratory infection

UR - http://www.scopus.com/inward/record.url?scp=85099104624&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/NHMRC/569246

U2 - 10.1136/thoraxjnl-2020-216331

DO - 10.1136/thoraxjnl-2020-216331

M3 - Article

AN - SCOPUS:85099104624

SN - 0040-6376

VL - 76

SP - 733

EP - 736

JO - Thorax

JF - Thorax

IS - 7

ER -

Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: An AMAZES substudy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this